metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)
versus placebo plus SoC
	pembrolizumab plus SoC
	KEYNOTE-590 unpublished Future Oncol 2019 Apr;15(10):1057-1066. Lancet. 2021 Aug 28;398(10302):759-771 NCT03189719	RCT	mEC - 1st line (L1)	Pembrolizumab with cisplatin and 5 FU :	placebo with cisplatin and 5 FU :	as first-line treatment in Subjects With Advanced/Metastatic Esophageal squamous Carcinoma or EGJ	373 / 376	NA	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) demonstrated 35 % decrease in progression or deaths (PFS) (PE) demonstrated 98 % increase in objective responses (ORR) (PE) Pembrolizumab (Keytruda) in combination with chemotherapy significantly improved overallsurvival (OS) and progressionfree survival (PFS) in the frontline treatment of patients with locally advanced or metastatic esophageal cancer, meeting the primary end points of the phase 3 KEYNOTE-590 trial
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-181, 2020 Journal of Clinical Oncology Journal of Clinical Oncology J Clin Oncol 2020 Dec 10;38(35):4138-4148. Pubmed J Clin Oncol 2021 Nov 3;JCO2100601. ESMO Open. 2022 Feb;7(1):100341. NCT02564263	RCT	mEC - 2nd line (L2)	Pembrolizumab	chemotherapy ICC (paclitaxel, docetaxel, or irinotecan)	Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus/ or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) That Have Progressed After First-Line Standard Therapy	314 / 314	NA	inconclusive	inconclusive 11 % decrease in deaths (OS) (PE) (Pembrolizumab significantly improved OS compared with chemo as second-line therapy for advanced esophageal cancer with PD-L1 CPS ≥10) => no stat plan